Efficacy News and Research

RSS

BuruliVac project getting closer to a vaccine

During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice.

19 Apr 2012

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

19 Apr 2012

ARVO to host presentation of results from two clinical trials on neovascular AMD

ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

19 Apr 2012

Autologous BMMNCs reduce vascular growth in patients with diabetes

Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have been found to significantly induce vascular growth when transplanted into patients with diabetes who are suffering from critical limb ischemia caused by peripheral artery disease (PAD), a complication of diabetes.

19 Apr 2012

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Presidio Pharmaceuticals, Inc. announced results today from a Phase 1a-1b clinical trial of PPI-668, a potent, pan-genotypic HCV NS5A inhibitor being developed for the treatment of patients with chronic hepatitis C.

19 Apr 2012

Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate.

19 Apr 2012

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Abbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).

18 Apr 2012

Medical journals facing raft of ethical, transparency challenges

The New York Times, Connecticut Mirror and MedPage Today examine how prominent journals are handling questions about their independence or integrity.

18 Apr 2012

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to initiate a Phase IIb multi-center, 100-patient clinical trial.

18 Apr 2012

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA.

18 Apr 2012

Autologous HSPPC-96 vaccine clinically beneficial for GBM patients

Study results from a Phase II multicenter clinical trial tracking the impact that autologous heat shock protein-peptide vaccine (HSPPC-96) has on recurrent glioblastoma multiforme (GBM) patients showed that such a vaccine may be clinically beneficial.

18 Apr 2012

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis.

18 Apr 2012

Study supports tolerability of low-dose aripiprazole as an antidepressant therapy-augmenting agent

In the current issue of Psychotherapy and Psychosomatics there is a negative study on the use of aripiprazole in depression.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

Medtronic plans IN.PACT Global drug-eluting balloon SFA clinical study

In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.

From Medtronic 18 Apr 2012

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

International Microbicides Conference to discuss state of HIV prevention research

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis.

17 Apr 2012

Inspiration submits IB1001 BLA with FDA for treatment of hemophilia B

Ipsen today announced that its partner, Inspiration Biopharmaceuticals, Inc., has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of IB1001, an intravenous recombinant factor IX (rFIX) for the treatment and prevention of bleeding in individuals with hemophilia B.

17 Apr 2012

Morphotek commences MORAb-004 Phase II study in metastatic colorectal cancer

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is refractory to all standard therapy.

17 Apr 2012

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Novasep, a provider of purification-based manufacturing solutions for lifescience molecules, has announced that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

16 Apr 2012

Efficacy News and Research

BuruliVac project getting closer to a vaccine

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

ARVO to host presentation of results from two clinical trials on neovascular AMD

Autologous BMMNCs reduce vascular growth in patients with diabetes

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Medical journals facing raft of ethical, transparency challenges

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Autologous HSPPC-96 vaccine clinically beneficial for GBM patients

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

Study supports tolerability of low-dose aripiprazole as an antidepressant therapy-augmenting agent

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Medtronic plans IN.PACT Global drug-eluting balloon SFA clinical study

Imaxio closes EUR 2.9 million funding round

International Microbicides Conference to discuss state of HIV prevention research

Inspiration submits IB1001 BLA with FDA for treatment of hemophilia B

Morphotek commences MORAb-004 Phase II study in metastatic colorectal cancer

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News